Trial
NCT04149574
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Urinary Bladder Neoplasms
Intervention
nivolumab
Why stopped
Insufficient enrollment, inability to meet protocol objectives, and slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-16